HighTower Advisors
CORT icon

HighTower Advisors’s Corcept Therapeutics CORT Stock Holding History

HighTower Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879K Sell
10,106
-1,827
-15% -$110K ﹤0.01% 2326
2026
Q1 		$481K Buy
11,933
+122
+1% +$4.56K ﹤0.01% 2748
2025
Q4 		$411K Sell
11,811
-35,093
-75% -$2.76M ﹤0.01% 2785
2025
Q3 		$3.9M Sell
46,904
-2,674
-5% -$194K ﹤0.01% 1254
2025
Q2 		$3.64M Sell
49,578
-50,674
-51% -$3.67M ﹤0.01% 1238
2025
Q1 		$11.5M Buy
100,252
+6,575
+7% +$400K 0.02% 705
2024
Q4 		$4.72M Buy
93,677
+22,011
+31% +$1.15M 0.01% 1073
2024
Q3 		$3.31M Sell
71,666
-5,839
-8% -$207K ﹤0.01% 1227
2024
Q2 		$2.52M Buy
77,505
+5,137
+7% +$141K ﹤0.01% 1326
2024
Q1 		$1.82M Buy
72,368
+55,042
+318% +$1.3M ﹤0.01% 1477
2023
Q4 		$570K Sell
17,326
-4,025
-19% -$111K ﹤0.01% 2223
2023
Q3 		$580K Buy
+21,351
New +$618K ﹤0.01% 2129
2018
Q1 		– Sell
-11,832
Closed -$215K – 2214
2017
Q4 		$215K Buy
+11,832
New +$214K ﹤0.01% 1876

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's CORT Position: Q2 2026 in Review

HighTower Advisors reduced its Corcept Therapeutics (CORT) stake by 15% in Q2 2026, selling an estimated $110K and leaving 10,106 shares worth $879K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

HighTower Advisors first reported a position in CORT in Q4 2017 and has held it in 13 quarters since. The position peaked at $11.5M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • HighTower Advisors held 10,106 shares of Corcept Therapeutics worth $879K as of Q2 2026.
  • HighTower Advisors sold 1,827 Corcept Therapeutics shares in Q2 2026, an estimated $110K.
  • Corcept Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2326 holding.
  • HighTower Advisors first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 13 quarters since.
  • HighTower Advisors's Corcept Therapeutics position peaked at $11.5M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.